Printer Friendly

InKine Pharmaceutical Appoints Stephen M. Casey as Vice President of Sales and Marketing.

BLUE BELL, Pa.--(BUSINESS WIRE)--Nov. 8, 1999--

InKine Pharmaceutical Company, Inc, (Nasdaq: INKP) today announced the appointment of Stephen M. Casey as Vice President of Sales and Marketing. Mr. Casey will be responsible for implementing the commercial launch strategy of Diacol, as well as other products that InKine develops.

Mr. Casey joins InKine from Schwarz Pharma Inc., where he was in a variety of marketing and sales positions of increasing responsibility since 1988. Most recently he was the Director of Management of Axcan Schwarz LLC, which was the joint venture between Axcan Pharma, a gastrointestinal pharmaceutical company and Schwarz Pharma. Mr. Casey oversaw the successful launch of URSO (ursodiol tablets) for the treatment of Primary Biliary Cirrhosis (PBC) a rare liver disease. Earlier in Mr. Casey's career he was marketing manager for all of Schwarz's gastrointestinal products including CoLyte,(TM) a liquid purgative product. In addition to overseeing the integration of all gastrointestinal products acquired by Schwarz Pharma, Mr. Casey also helped train the substantial sales forces acquired from Reed & Carnrick and Central Pharmaceuticals.

"We are fortunate to have attracted such an accomplished executive to oversee the commercial launch of Diacol"(TM) said Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine. "Steve brings to InKine a wealth of marketing and sales experience in gastrointestinal products which should benefit InKine as we prepare our marketing and sales strategies for Diacol, our purgative agent in tablet form for adult patients undergoing colonoscopic evaluation."

InKine Pharmaceutical Company, Inc, is a publicly traded, biopharmaceutical company with two late-stage clinical compounds: Diacol, a purgative product for colonoscopies and other procedures and uses; and CBP-1011, a steroid molecule for treatment of Idiopathic Thrombocytopenic Purpura (ITP). The Company is focused on the diagnosis and treatment of cancer and autoimmune diseases, and has the additional strategy of acquiring late-stage drug candidates with short time lines to commercialization. Support of early-stage product opportunities comes through its university-based sponsored research agreements.

This announcement contains certain forward-looking statements that are subject to risks and uncertainties, including in particular the statement regarding the commercial launch of Diacol. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties discussed under "Other Factors to be Considered" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1999, as filed with the Securities and Exchange Commission.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 8, 1999
Previous Article:Industri-Matematik Awarded Worldwide Call Center Contract to Supply Volvo Action Service with a Customer Relationship Management Solution.
Next Article:Mesa Systems Guild Signs 6-year Agreement with Lockheed Martin Management & Data Systems.

Related Articles
InKine Pharmaceutical Elects Robert A. Vukovich, Ph.D. to Board of Directors.
Michael D. Casey of Matrix Pharmaceutical Joins Cholestech Board of Directors.
InKine Reports First Quarter 2001 Financial Results.
InKine Announces Launch of Pivotal Trial of Colirest in Crohn's Disease.
InKine Announces Zeria Pharmaceutical to License Visicol for Japan.
InKine Reports Third Quarter Financial Results; Implements Significant Cost Reductions.
InKine Reports Fourth Quarter and Year-end Financial Results.
InKine Announces FDA Approval of "New Formulation" of Visicol; SNDA Approved Under Expedited Review.
InKine Modifies Procter & Gamble Co-Promotion Agreement for Visicol-TM-: Incentives Based On Prescription Growth.
InKine Reports First Quarter Financial Results.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters